RVLP · Rvl Pharmaceuticals PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | $49.72M | $17.50M | $177.88M | $240.03M | $245.75M |
| Cost of Revenue | $9.46M | $3.62M | $74.48M | $111.63M | $125.19M |
| Gross Profit | $40.27M | $13.88M | $103.40M | $128.40M | $120.56M |
| R&D | $3.97M | $6.93M | $19.70M | $32.32M | $42.69M |
| SG&A | $81.98M | $87.46M | $81.96M | $93.03M | $56.95M |
| Total Operating Expenses | $99.25M | $102.27M | $173.84M | $409.10M | $172.63M |
| D&A | $375.0K | $8.18M | $21.03M | $57.02M | $46.45M |
| Operating Income | ($58.99M) | ($82.75M) | ($70.44M) | ($280.69M) | ($52.07M) |
| Interest Expense | $3.11M | $3.04M | $14.40M | $18.21M | $29.05M |
| Income Tax | $20.0K | ($315.0K) | ($4.70M) | ($27.12M) | ($44.50M) |
| Net Income | ($51.69M) | ($64.92M) | ($79.59M) | ($270.90M) | ($41.14M) |
| EPS - Basic | ($0.58) | ($1.31) | - | - | - |
| EPS - Diluted | ($0.58) | ($1.31) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $44.54M | $40.44M | $114.05M | $95.86M | $70.83M |
| Accounts Receivable | $947.0K | $2.13M | $26.41M | $43.91M | $56.42M |
| Inventory | $784.0K | $838.0K | $17.93M | $21.30M | $24.38M |
| Accounts Payable | $2.41M | $3.78M | $6.77M | $8.49M | $24.87M |
| Current Assets | $56.98M | $59.38M | $173.15M | $172.63M | $172.39M |
| Total Assets | $128.51M | $144.67M | $370.95M | $463.25M | $795.64M |
| Current Liabilities | $19.72M | $20.11M | $55.78M | $75.94M | $114.39M |
| Long-term Debt | $75.00M | $55.00M | $219.53M | $267.95M | $266.80M |
| Total Liabilities | $77.42M | $67.94M | $277.09M | $348.55M | $409.38M |
| Stockholders' Equity | $51.09M | $76.73M | $93.86M | $114.71M | $386.27M |
| Retained Earnings | ($569.22M) | ($517.53M) | ($452.61M) | ($373.02M) | ($102.36M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($37.81M) | ($54.73M) | $17.59M | $33.57M | $57.84M |
| Investing Cash Flow | $126.0K | $116.45M | ($3.08M) | ($4.02M) | ($19.40M) |
| Financing Cash Flow | $41.78M | ($135.33M) | $3.68M | ($4.69M) | ($23.31M) |
| CapEx | $752.0K | $1.78M | $2.92M | $3.96M | $6.90M |
| Free Cash Flow | ($38.56M) | ($56.51M) | $14.67M | $29.60M | $50.94M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 81.0% | 79.3% | 58.1% | 53.5% | 49.1% |
| Operating margin | -118.6% | -472.9% | -39.6% | -116.9% | -21.2% |
| EBITDA margin | -117.9% | -426.1% | -27.8% | -93.2% | -2.3% |
| Net margin | -104.0% | -371.0% | -44.7% | -112.9% | -16.7% |
| Free cash flow margin | -77.6% | -322.9% | 8.2% | 12.3% | 20.7% |
| FCF / Net income | 0.75 | 0.87 | -0.18 | -0.11 | -1.24 |
| R&D / Revenue | 8.0% | 39.6% | 11.1% | 13.5% | 17.4% |
| SG&A / Revenue | 164.9% | 499.8% | 46.1% | 38.8% | 23.2% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -40.2% | -44.9% | -21.5% | -58.5% | -5.2% |
| Return on equity | -101.2% | -84.6% | -84.8% | -236.2% | -10.7% |
| Return on invested capital | -37.0% | -49.6% | -17.8% | -57.9% | -6.3% |
| Liquidity | |||||
| Current ratio | 2.89 | 2.95 | 3.10 | 2.27 | 1.51 |
| Quick ratio | 2.85 | 2.91 | 2.78 | 1.99 | 1.29 |
| Cash ratio | 2.26 | 2.01 | 2.04 | 1.26 | 0.62 |
| Leverage | |||||
| Debt / Equity | 1.47 | 0.72 | 2.34 | 2.34 | 0.69 |
| Debt / Assets | 0.58 | 0.38 | 0.59 | 0.58 | 0.34 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -19.0x | -27.3x | -4.9x | -15.4x | -1.8x |
| Equity multiplier | 2.52 | 1.89 | 3.95 | 4.04 | 2.06 |
| Liabilities / Assets | 0.60 | 0.47 | 0.75 | 0.75 | 0.51 |
| Efficiency | |||||
| Asset turnover | 0.39 | 0.12 | 0.48 | 0.52 | 0.31 |
| Inventory turnover | 12.06 | 4.32 | 4.15 | 5.24 | 5.13 |
| Days sales outstanding | 7d | 44d | 54d | 67d | 84d |
| Days inventory outstanding | 30d | 85d | 88d | 70d | 71d |
| Days payable outstanding | 93d | 381d | 33d | 28d | 73d |
| Cash conversion cycle | -56d | -252d | 109d | 109d | 82d |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 184.1% | -90.2% | -25.9% | -2.3% | - |
| Revenue CAGR (3y) | -40.8% | -58.6% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 190.0% | -86.6% | -19.5% | 6.5% | - |
| Operating income growth (YoY) | 28.7% | -17.5% | 74.9% | -439.1% | - |
| Net income growth (YoY) | 20.4% | 18.4% | 70.6% | -558.5% | - |
| EPS growth (YoY) | 55.7% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 31.8% | - | -50.4% | -41.9% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -33.4% | -18.2% | -18.2% | -70.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$35.01M totalLicense And Contract Revenue$10.00M · 28.6%
Royalty And Licensing Revenue$9.99M · 28.5%
Upneeq Product$7.51M · 21.5%
Product$7.51M · 21.5%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-4.31
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing RVL Pharmaceuticals plc against the 5 most active filers in the same SIC group.